Literature DB >> 32233163

Understanding and Interpretation of Case Fatality Rate of Coronavirus Disease 2019.

Dong Hyun Kim1,2, Young June Choe1, Jin Young Jeong3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32233163      PMCID: PMC7105506          DOI: 10.3346/jkms.2020.35.e137

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


× No keyword cloud information.
As we have entered several months in the influence of coronavirus disease-19 (COVID-19), there are ongoing surge of cases in many parts of the world.1 Amongst, Republic of Korea was one of the countries with the largest number of cases in the early phase of this outbreak and has tested far more than most countries.12 Case fatality rate (CFR) is the proportion of the number of deaths divided by the number of confirmed patients of a disease, which has been used to assess and compare the severity of the epidemic between countries. The rates can also be used to assess the healthcare capacity in response to the outbreak. To date, there appear to be wide variations in CFR of COVID-19 among countries (Fig. 1). The current CFR in Korea is 1.3% (120 deaths out of 9,037 confirmed cases), as of March 25, 2020,2 while the CFRs are 9.5% in Italy, 7.9% in Iran, 6.6% in Spain, and 4.0% in China.1
Fig. 1

Case fatality rates in selected countries with confirmed cases and death from coronavirus disease 2019, as of March 25, 2020.

Reproduced from: World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report–64. Geneva: World Health Organization; 2020.

The crude rate from aggregated data (the total number of deaths divided by the total number of cases) does not give a timely estimate during the course of the outbreak. The final CFR will be different from the early outbreak as the report of affected person's outcome will be delayed inherently. Change in CFR in the progress of an epidemic has been observed in other outbreaks of novel viruses. In the earlier phase of severe acute respiratory syndrome epidemic in 2003, the CFR was reported to be less than 4%, which was ended up to be 9.6%.3 Reports on the COVID-19's CFR also varied by timeline that started from 5.8% to 1.4% in Wuhan, China.4 The exact CFR from COVID-19 that reflects the true disease severity will likely be unveiled when the dust settles down after weeks or months. Moreover, the current CFRs place ‘reported’ number of deaths in the numerator and ‘reported’ number of confirmed cases in the denominator in each country. It may not reflect the true number of deaths (numerator) and COVID-19 cases (denominator) occurred in each country. Given the difference of testing capabilities and public health response policy for detection of COVID-19 cases between countries, it is imperative to check the completeness of death reports following COVID-19, before making a comparison between the countries. It is also dependent on each country's surveillance performance to detect cases of COVID-19. It is speculated that most of asymptomatic or presymptomatic cases would not be tested for COVID-19 in many places, resulting in higher CFR by smaller denominator. The age structure of affected population should be also accounted for a fair comparison. In Korea, the low CFR, 1.3% as of March 25, 2020, could have resulted from the larger proportion of younger confirmed cases resulting larger denominator of low-risk population. Difference in age structure of affected population between countries may guide to the true burden of COVID-19 in terms of disease severity and fatality proportions. Age-specific or age-stratified CFR will be useful in comparing between the countries with different affected age groups. Table 1 shows number of deaths and age-specific CFRs of Korea, Italy, and China.25 Crude CFR in Korea appears to be one fifth lower than that of Italy (1.3% vs. 7.2%), but the difference between the two countries sharply decreases among the individuals older than 70. Thus, taking the age structure of confirmed cases into account is crucial for a fair comparison as it shows the difference in the age-adjusted CFR between the two countries is considerably reduced (2.4% vs. 4.2%).
Table 1

Age-specific and adjusted CFR in Korea, Italy, and Chinaa

Age groups, yrKorea, as of March 24, 2020Italy, as of March 17, 2020China, as of February 11, 2020
No. of deathCFR, %No. of deathCFR, %No. of deathCFR, %
0–900.000.000.0
10–1900.000.010.2
20–2900.000.070.2
30–3910.140.3180.2
40–4910.1100.4380.4
50–5980.6431.01301.3
60–69201.71393.53093.6
70–79386.457812.83128.0
80+5213.685020.220814.8
Total1201.31,6247.21,0232.3
Age adj. CFRb2.44.23.2

CFR = case fatality rate.

aMinistry of Health and Welfare, Republic of Korea, March 25, 20205; bAdjusted to the age distribution of total confirmed cases of three countries combined.

Lastly, CFR should be interpreted cautiously given the time difference between disease onset and death. Fatal cases used to be ascertained as COVID-19 cases much earlier, and thus the denominator of the fatality rate should be the total number of cases confirmed at the same time as those who died in the numerator. That is, the denominator and the numerator of CFR should be composed of patients infected at the same time as those who died in order to accurately represent the actual CFR.6 Most of the recently diagnosed patients in many countries are still likely to be in the care-state. That is, the cross-sectional comparison of these figures may be biased since the time span for illness is different among countries during the course of the ongoing epidemic. To avoid this bias, time-delay adjusted estimates between symptom onset and death need to be calculated for a fair comparison of CFRs among different countries.7 Russell et al.8 proposed a delay-adjusted CFR to correct the delay between confirmation-and-death, using the distribution of the delay from hospitalization-to-death for cases that are fatal from Wuhan, China. In conclusion, estimating the CFR is a high priority in response to COVID-19 pandemic. Yet, its interpretation must be made cautiously during the middle of outbreak as such biases should be considered before drawing causal inferences from observational data. Collection in-depth analysis of fatality data in systematic manner should be in place in near future.
  3 in total

1.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.

Authors:  Graziano Onder; Giovanni Rezza; Silvio Brusaferro
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

Review 2.  SARS: the new challenge to international health and travel medicine.

Authors:  S Venkatesh; Z A Memish
Journal:  East Mediterr Health J       Date:  2004 Jul-Sep       Impact factor: 1.628

3.  Real estimates of mortality following COVID-19 infection.

Authors:  David Baud; Xiaolong Qi; Karin Nielsen-Saines; Didier Musso; Léo Pomar; Guillaume Favre
Journal:  Lancet Infect Dis       Date:  2020-03-12       Impact factor: 25.071

  3 in total
  19 in total

Review 1.  Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.

Authors:  Sarah Mousavi; Shima Zare; Mahmoud Mirzaei; Awat Feizi
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-09-25       Impact factor: 2.585

2.  Association of COVID-19 Case-Fatality Rate With State Health Disparity in the United States.

Authors:  Yu-Che Lee; Ko-Yun Chang; Mehdi Mirsaeidi
Journal:  Front Med (Lausanne)       Date:  2022-06-29

3.  COVID-19 Pandemic: Global Impact and Potential Implications for Cardiovascular Disease in Canada.

Authors:  Leigh C P Botly; Michelle Martin-Rhee; Adrienne Kasiban; Richard H Swartz; Sharon L Mulvagh; M Patrice Lindsay; Cristina Goia; Eric E Smith; Michael D Hill; Thalia S Field; Andrew D Krahn; Gavin Y Oudit; Shelley Zieroth; Cindy Y Y Yip
Journal:  CJC Open       Date:  2020-06-06

4.  Early Experiences With COVID-19 Testing in Transplantation.

Authors:  Brian J Boyarsky; Allan B Massie; Arthur D Love; William A Werbel; Christine M Durand; Robin K Avery; Kyle R Jackson; Amber B Kernodle; Alvin G Thomas; Matthew Ronin; Michelle Altrich; Patricia Niles; Chad Trahan; Jonathan Hewlett; Dorry L Segev; Jacqueline M Garonzik-Wang
Journal:  Transplant Direct       Date:  2020-06-11

Review 5.  Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review.

Authors:  SeyedAhmad SeyedAlinaghi; Pegah Mirzapour; Omid Dadras; Zahra Pashaei; Amirali Karimi; Mehrzad MohsseniPour; Mahdi Soleymanzadeh; Alireza Barzegary; Amir Masoud Afsahi; Farzin Vahedi; Ahmadreza Shamsabadi; Farzane Behnezhad; Solmaz Saeidi; Esmaeil Mehraeen
Journal:  Eur J Med Res       Date:  2021-06-08       Impact factor: 2.175

6.  Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.

Authors:  Vanessa Piechotta; Claire Iannizzi; Khai Li Chai; Sarah J Valk; Catherine Kimber; Elena Dorando; Ina Monsef; Erica M Wood; Abigail A Lamikanra; David J Roberts; Zoe McQuilten; Cynthia So-Osman; Lise J Estcourt; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2021-05-20

7.  Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.

Authors:  Sarah J Valk; Vanessa Piechotta; Khai Li Chai; Carolyn Doree; Ina Monsef; Erica M Wood; Abigail Lamikanra; Catherine Kimber; Zoe McQuilten; Cynthia So-Osman; Lise J Estcourt; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

Review 8.  Age-Related Morbidity and Mortality among Patients with COVID-19.

Authors:  Seung Ji Kang; Sook In Jung
Journal:  Infect Chemother       Date:  2020-06-12

9.  Comorbidities and Factors Determining Medical Expenses and Length of Stay for Admitted COVID-19 Patients in Korea.

Authors:  Su Yeon Jang; Jeong-Yeon Seon; Seung Heon Lee; In-Hwan Oh; Seok-Jun Yoon; So-Youn Park
Journal:  Risk Manag Healthc Policy       Date:  2021-05-18

10.  Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study.

Authors:  Allan B Massie; Brian J Boyarsky; William A Werbel; Sunjae Bae; Eric K H Chow; Robin K Avery; Christine M Durand; Niraj Desai; Daniel Brennan; Jacqueline M Garonzik-Wang; Dorry L Segev
Journal:  Am J Transplant       Date:  2020-07-15       Impact factor: 9.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.